Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	antigen binding	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	3.81e-32	190	35	20	GO:0003823
GeneOntologyMolecularFunction	5-methylcytosine dioxygenase activity	TET2 TET3 TET1	4.93e-09	3	35	3	GO:0070579
GeneOntologyMolecularFunction	2-oxoglutarate-dependent dioxygenase activity	TET2 TET3 TET1	2.00e-04	65	35	3	GO:0016706
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	TET2 PAM TET3 TET1	3.57e-04	194	35	4	GO:0016705
GeneOntologyMolecularFunction	natural killer cell lectin-like receptor binding	ULBP2 HLA-G	3.99e-04	17	35	2	GO:0046703
GeneOntologyMolecularFunction	dioxygenase activity	TET2 TET3 TET1	6.69e-04	98	35	3	GO:0051213
GeneOntologyMolecularFunction	methyl-CpG binding	TET3 TET1	1.34e-03	31	35	2	GO:0008327
GeneOntologyBiologicalProcess	B cell mediated immunity	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	3.63e-30	244	35	20	GO:0019724
GeneOntologyBiologicalProcess	immunoglobulin mediated immune response	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	1.97e-28	235	35	19	GO:0016064
GeneOntologyBiologicalProcess	lymphocyte mediated immunity	IGHV3-49 IGHV3-48 ULBP2 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	1.37e-26	449	35	21	GO:0002449
GeneOntologyBiologicalProcess	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	IGHV3-49 IGHV3-48 ULBP2 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	2.50e-26	462	35	21	GO:0002460
GeneOntologyBiologicalProcess	leukocyte mediated immunity	IGHV3-49 IGHV3-48 ULBP2 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	2.61e-24	576	35	21	GO:0002443
GeneOntologyBiologicalProcess	adaptive immune response	IGHV3-49 IGHV3-48 ULBP2 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	6.47e-21	838	35	21	GO:0002250
GeneOntologyBiologicalProcess	immune effector process	IGHV3-49 IGHV3-48 ULBP2 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D HLA-G	1.08e-20	859	35	21	GO:0002252
GeneOntologyBiologicalProcess	positive regulation of gene expression via chromosomal CpG island demethylation	TET2 TET3 TET1	2.01e-06	15	35	3	GO:0044029
GeneOntologyBiologicalProcess	epigenetic programing of male pronucleus	TET3 TET1	2.79e-05	5	35	2	GO:0044727
GeneOntologyBiologicalProcess	pyrimidine-containing compound catabolic process	TET2 TET3 TET1	6.46e-05	46	35	3	GO:0072529
GeneOntologyBiologicalProcess	transcription initiation-coupled chromatin remodeling	TET2 TET3 TET1	1.82e-04	65	35	3	GO:0045815
GeneOntologyBiologicalProcess	positive regulation of gene expression, epigenetic	TET2 TET3 TET1	2.08e-04	68	35	3	GO:0141137
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	ULBP2 HLA-G	3.31e-04	16	35	2	GO:0002486
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway	ULBP2 HLA-G	3.74e-04	17	35	2	GO:0002484
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous peptide antigen via MHC class Ib	ULBP2 HLA-G	3.74e-04	17	35	2	GO:0002476
GeneOntologyBiologicalProcess	epigenetic programming in the zygotic pronuclei	TET3 TET1	3.74e-04	17	35	2	GO:0044725
GeneOntologyBiologicalProcess	antigen processing and presentation of peptide antigen via MHC class Ib	ULBP2 HLA-G	4.21e-04	18	35	2	GO:0002428
GeneOntologyBiologicalProcess	pyrimidine-containing compound metabolic process	TET2 TET3 TET1	5.07e-04	92	35	3	GO:0072527
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous peptide antigen via MHC class I	ULBP2 HLA-G	6.92e-04	23	35	2	GO:0019885
GeneOntologyBiologicalProcess	protein O-linked glycosylation	TET2 TET3 TET1	7.45e-04	105	35	3	GO:0006493
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous peptide antigen	ULBP2 HLA-G	8.19e-04	25	35	2	GO:0002483
GeneOntologyBiologicalProcess	antigen processing and presentation via MHC class Ib	ULBP2 HLA-G	8.19e-04	25	35	2	GO:0002475
GeneOntologyBiologicalProcess	antigen processing and presentation of endogenous antigen	ULBP2 HLA-G	1.34e-03	32	35	2	GO:0019883
GeneOntologyBiologicalProcess	positive regulation of natural killer cell mediated cytotoxicity	ULBP2 HLA-G	2.10e-03	40	35	2	GO:0045954
GeneOntologyBiologicalProcess	antigen processing and presentation of peptide antigen via MHC class I	ULBP2 HLA-G	2.20e-03	41	35	2	GO:0002474
GeneOntologyBiologicalProcess	positive regulation of T cell mediated cytotoxicity	ULBP2 HLA-G	2.31e-03	42	35	2	GO:0001916
GeneOntologyBiologicalProcess	positive regulation of natural killer cell mediated immunity	ULBP2 HLA-G	2.53e-03	44	35	2	GO:0002717
GeneOntologyCellularComponent	immunoglobulin complex	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	1.58e-31	166	35	19	GO:0019814
GeneOntologyCellularComponent	blood microparticle	IGHV3-23 IGHV3-13 EIF2A IGHV3-7	9.58e-05	144	35	4	GO:0072562
MousePheno	multi-headed sperm	GMCL1 GMCL2	6.75e-06	5	12	2	MP:0031408
MousePheno	multiflagellated sperm	GMCL1 GMCL2	6.11e-05	14	12	2	MP:0009839
Domain	Tet_JBP	TET2 TET1	6.02e-07	2	15	2	PF12851
Domain	2OGFeDO_noxygenase_dom	TET2 TET1	6.02e-07	2	15	2	IPR024779
Domain	Tet_JBP	TET2 TET1	6.02e-07	2	15	2	SM01333
Domain	MHC_I_a_a1/a2	ULBP2 HLA-G	1.25e-04	21	15	2	IPR001039
Domain	MHC_I	ULBP2 HLA-G	1.25e-04	21	15	2	PF00129
Domain	-	ULBP2 HLA-G	1.64e-04	24	15	2	3.30.500.10
Domain	MHC_I-like_Ag-recog	ULBP2 HLA-G	1.64e-04	24	15	2	IPR011161
Domain	MHC_I/II-like_Ag-recog	ULBP2 HLA-G	4.16e-04	38	15	2	IPR011162
Domain	Ig/MHC_CS	ULBP2 HLA-G	9.70e-04	58	15	2	IPR003006
Domain	IG_MHC	ULBP2 HLA-G	1.04e-03	60	15	2	PS00290
Domain	BTB	GMCL1 GMCL2	4.83e-03	131	15	2	PF00651
Domain	BTB	GMCL1 GMCL2	7.12e-03	160	15	2	PS50097
Domain	BTB	GMCL1 GMCL2	8.93e-03	180	15	2	SM00225
Domain	BTB/POZ_dom	GMCL1 GMCL2	9.41e-03	185	15	2	IPR000210
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	2.65e-24	35	22	11	MM17219
Pathway	REACTOME_CLASSICAL_ANTIBODY_MEDIATED_COMPLEMENT_ACTIVATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.06e-23	39	22	11	MM17212
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	6.41e-23	45	22	11	MM14912
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.42e-22	48	22	11	MM17214
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	4.79e-22	53	22	11	MM15716
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	6.01e-22	54	22	11	MM14655
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	9.33e-22	56	22	11	MM14815
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.42e-21	58	22	11	MM14914
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	2.14e-21	60	22	11	MM14872
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	2.14e-21	60	22	11	MM14913
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.14e-19	84	22	11	MM14653
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D HLA-G	2.15e-19	135	22	12	MM14781
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.87e-18	107	22	11	MM14915
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	3.87e-18	114	22	11	MM14814
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.88e-17	131	22	11	MM15717
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	8.71e-17	150	22	11	MM14889
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.56e-16	158	22	11	MM14812
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D HLA-G	1.14e-10	719	22	12	MM14540
Pathway	REACTOME_HEMOSTASIS	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	2.06e-10	571	22	11	MM14472
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	3.61e-10	61	22	6	M27581
Pathway	REACTOME_VESICLE_MEDIATED_TRANSPORT	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	7.53e-10	645	22	11	MM15232
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	7.73e-10	69	22	6	M27108
Pathway	REACTOME_SCAVENGING_OF_HEME_FROM_PLASMA	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	7.73e-10	69	22	6	M27150
Pathway	REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	9.21e-10	71	22	6	M1078
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	9.21e-10	71	22	6	M27203
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	1.92e-09	80	22	6	M6121
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	2.23e-09	82	22	6	M27110
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	2.98e-09	86	22	6	M601
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	2.98e-09	86	22	6	M27206
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	3.20e-09	87	22	6	M27205
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D HLA-G	4.78e-09	995	22	12	MM14661
Pathway	REACTOME_FCGR3A_MEDIATED_IL10_SYNTHESIS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	5.46e-09	95	22	6	M29842
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	6.59e-09	98	22	6	M27152
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 HLA-G	1.04e-08	190	22	7	M8240
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	1.73e-08	115	22	6	M19752
Pathway	REACTOME_PARASITE_INFECTION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	1.83e-08	116	22	6	M29843
Pathway	REACTOME_ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	4.34e-08	134	22	6	M29840
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	4.74e-08	136	22	6	M27207
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	6.40e-08	143	22	6	M27107
Pathway	REACTOME_POTENTIAL_THERAPEUTICS_FOR_SARS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	9.96e-08	154	22	6	M39007
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	1.55e-07	166	22	6	M608
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	3.05e-07	186	22	6	M27175
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	3.90e-07	194	22	6	M16312
Pathway	REACTOME_LEISHMANIA_INFECTION	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	7.96e-07	219	22	6	M29836
Pathway	REACTOME_SARS_COV_INFECTIONS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 HLA-G	4.90e-06	471	22	7	M39009
Pathway	WP_CYTOSINE_METHYLATION	TET2 TET1	6.47e-05	8	22	2	M39348
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 HLA-G	1.84e-04	828	22	7	M1058
Pathway	WP_MECP2_AND_ASSOCIATED_RETT_SYNDROME	TET2 TET3 TET1	1.91e-04	73	22	3	M39401
Pathway	REACTOME_VIRAL_INFECTION_PATHWAYS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 HLA-G	2.84e-04	888	22	7	M48034
Pathway	REACTOME_HEMOSTASIS	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	4.69e-04	679	22	6	M8395
Pathway	REACTOME_VESICLE_MEDIATED_TRANSPORT	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	6.65e-04	725	22	6	M27507
Pathway	REACTOME_INFECTIOUS_DISEASE	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 HLA-G	9.35e-04	1081	22	7	M27548
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-48 IGHV3-33 MUC5B IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7	1.20e-03	1128	22	7	M1036
Pathway	REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION	TET2 TET3 TET1	6.91e-03	254	22	3	M27131
Pathway	KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	ULBP2 HLA-G	1.91e-02	137	22	2	M5669
Pubmed	IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes.	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	1.10e-31	77	35	15	15608191
Pubmed	1.3 A X-ray structure of an antibody Fv fragment used for induced membrane-protein crystallization.	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	2.52e-31	15	35	11	12657787
Pubmed	Early onset of somatic mutation in immunoglobulin VH genes during the primary immune response.	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.30e-28	22	35	11	2499654
Pubmed	The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-20 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72	3.84e-23	91	35	12	9841928
Pubmed	Structure and physical map of 64 variable segments in the 3'0.8-megabase region of the human immunoglobulin heavy-chain locus.	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-20 IGHV3-9 IGHV3-7	8.29e-15	39	35	7	8490662
Pubmed	Molecular analysis of spontaneous somatic mutants.	IGHV3-48 IGHV3-21 IGHV3-13 IGHV3-7	4.29e-12	5	35	4	401950
Pubmed	Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region.	IGHV3-48 IGHV3-21 IGHV3-13 IGHV3-7 IGHV1-3	6.50e-12	18	35	5	6788376
Pubmed	Expression of TET and 5-HmC in Trophoblast Villi of Women with Normal Pregnancy and with Early Pregnancy Loss.	TET2 TET3 TET1	9.34e-10	3	35	3	30074219
Pubmed	Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter.	TET2 TET3 TET1	9.34e-10	3	35	3	24194590
Pubmed	TET proteins in malignant hematopoiesis.	TET2 TET3 TET1	9.34e-10	3	35	3	19923888
Pubmed	5-Hydroxymethylcytosine-mediated active demethylation is required for mammalian neuronal differentiation and function.	TET2 TET3 TET1	9.34e-10	3	35	3	34919053
Pubmed	Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells.	TET2 TET3 TET1	9.34e-10	3	35	3	24958354
Pubmed	Selective targeting of TET catalytic domain promotes somatic cell reprogramming.	TET2 TET3 TET1	9.34e-10	3	35	3	32024762
Pubmed	Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs.	TET2 TET3 TET1	9.34e-10	3	35	3	27184841
Pubmed	One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.	TET2 TET3 TET1	9.34e-10	3	35	3	23643243
Pubmed	Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine.	TET2 TET3 TET1	9.34e-10	3	35	3	21778364
Pubmed	Stage-specific regulation of DNA methylation by TET enzymes during human cardiac differentiation.	TET2 TET3 TET1	9.34e-10	3	35	3	34879277
Pubmed	Tet family proteins and 5-hydroxymethylcytosine in development and disease.	TET2 TET3 TET1	9.34e-10	3	35	3	22569552
Pubmed	Oxygen regulation of TET enzymes.	TET2 TET3 TET1	9.34e-10	3	35	3	33410283
Pubmed	Effect of aging on 5-hydroxymethylcytosine in brain mitochondria.	TET2 TET3 TET1	9.34e-10	3	35	3	22445327
Pubmed	Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.	TET2 TET3 TET1	9.34e-10	3	35	3	19372391
Pubmed	Loss of Tet enzymes compromises proper differentiation of embryonic stem cells.	TET2 TET3 TET1	9.34e-10	3	35	3	24735881
Pubmed	Differential expression of ten-eleven translocation genes in endometrial cancers.	TET2 TET3 TET1	9.34e-10	3	35	3	28349832
Pubmed	Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.	TET2 TET3 TET1	9.34e-10	3	35	3	20639862
Pubmed	Ten-Eleven Translocation Genes are Downregulated in Endometriosis.	TET2 TET3 TET1	9.34e-10	3	35	3	26917261
Pubmed	Mechanisms of TET protein-mediated DNA demethylation and its role in the regulation of mouse development.	TET2 TET3 TET1	9.34e-10	3	35	3	25608811
Pubmed	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.	TET2 TET3 TET1	9.34e-10	3	35	3	19420352
Pubmed	Alternation of ten-eleven translocation 1, 2, and 3 expression in eutopic endometrium of women with endometriosis-associated infertility.	TET2 TET3 TET1	9.34e-10	3	35	3	30130982
Pubmed	Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation.	TET2 TET3 TET1	9.34e-10	3	35	3	28218476
Pubmed	Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine.	TET2 TET3 TET1	9.34e-10	3	35	3	23548903
Pubmed	Regulation of DNA methylation signatures on NF-κB and STAT3 pathway genes and TET activity in cigarette smoke extract-challenged cells/COPD exacerbation model in vitro.	TET2 TET3 TET1	9.34e-10	3	35	3	32342329
Pubmed	TET1 Directs Chondrogenic Differentiation by Regulating SOX9 Dependent Activation of Col2a1 and Acan In Vitro.	TET2 TET3 TET1	3.73e-09	4	35	3	33134768
Pubmed	Tet-mediated DNA demethylation regulates specification of hematopoietic stem and progenitor cells during mammalian embryogenesis.	TET2 TET3 TET1	3.73e-09	4	35	3	35235365
Pubmed	An immunoglobulin promoter region is unaltered by DNA rearrangement and somatic mutation during B-cell development.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	6296789
Pubmed	Clonal Progression during the T Cell-Dependent B Cell Antibody Response Depends on the Immunoglobulin DH Gene Segment Repertoire.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	25157256
Pubmed	Phosphorylation of TET proteins is regulated via O-GlcNAcylation by the O-linked N-acetylglucosamine transferase (OGT).	TET2 TET3 TET1	3.73e-09	4	35	3	25568311
Pubmed	Defective secretion of an immunoglobulin caused by mutations in the heavy chain complementarity determining region 2.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	8046334
Pubmed	A biological consequence of variation in the site of D-JH gene rearrangement.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	6434992
Pubmed	Mouse monoclonal antibodies to pneumococcal C-polysaccharide backbone show restricted usage of VH-DH-JH gene segments and share the same kappa chain.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	19428559
Pubmed	Structure of the T15 VH gene subfamily: identification of immunoglobulin gene promotor homologies.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	3108392
Pubmed	Immunoglobulin heavy chain gene organization in mice: analysis of a myeloma genomic clone containing variable and alpha constant regions.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	106394
Pubmed	The D segment defines the T15 idiotype: the immunoresponse of A/J mice to Pneumococcus pneumoniae.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	6499907
Pubmed	Size differences among immunoglobulin heavy chains from phosphorylcholine-binding proteins.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	819932
Pubmed	Somatic hypermutation of an immunoglobulin transgene in kappa transgenic mice.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	3104790
Pubmed	Somatic evolution of diversity among anti-phosphocholine antibodies induced with Proteus morganii.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	3106498
Pubmed	Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine.	TET2 TET3 TET1	3.73e-09	4	35	3	21321204
Pubmed	Paradoxical association of TET loss of function with genome-wide DNA hypomethylation.	TET2 TET3 TET1	3.73e-09	4	35	3	31371502
Pubmed	Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked β-N-acetylglucosamine transferase (OGT).	TET2 TET3 TET1	3.73e-09	4	35	3	24394411
Pubmed	A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	2005389
Pubmed	An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	6769593
Pubmed	Repertoire shift in the humoral response to phosphocholine-keyhole limpet hemocyanin: VH somatic mutation in germinal center B cells impairs T15 Ig function.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	12734355
Pubmed	Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	2748602
Pubmed	Idiotype-specific Th cells support oligoclonal expansion of anti-dsDNA B cells in mice with lupus.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	25127856
Pubmed	Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	21068211
Pubmed	Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	8750831
Pubmed	Activation-induced cytidine deaminase alters the subcellular localization of Tet family proteins.	TET2 TET3 TET1	3.73e-09	4	35	3	23028748
Pubmed	Antibody diversity: somatic hypermutation of rearranged VH genes.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	6101208
Pubmed	Sequence and fine specificity analysis of primary 511 anti-phosphorylcholine antibodies.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	2512348
Pubmed	Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules.	TET2 TET3 TET1	3.73e-09	4	35	3	30554962
Pubmed	Crossreactive B cells are present during a primary but not secondary response in BALB/c mice expressing a bcl-2 transgene.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	10449099
Pubmed	The intrinsic and extrinsic effects of TET proteins during gastrulation.	TET2 TET3 TET1	3.73e-09	4	35	3	35908548
Pubmed	Developmentally controlled expression of immunoglobulin VH genes.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	3975629
Pubmed	Specific H chain junctional diversity may be required for non-T15 antibodies to bind phosphorylcholine.	IGHV3-49 IGHV3-73 IGHV3-72	3.73e-09	4	35	3	3135325
Pubmed	CD4 expression in effector T cells depends on DNA demethylation over a developmentally established stimulus-responsive element.	TET2 TET3 TET1	9.32e-09	5	35	3	35304452
Pubmed	IgD+IgM- B cells mount immune responses that exhibit altered antibody repertoire.	IGHV3-49 IGHV3-73 IGHV3-72	9.32e-09	5	35	3	14991595
Pubmed	DNA demethylation fine-tunes IL-2 production during thymic regulatory T cell differentiation.	TET2 TET3 TET1	9.32e-09	5	35	3	36880575
Pubmed	Increased junctional diversity in fetal B cells results in a loss of protective anti-phosphorylcholine antibodies in adult mice.	IGHV3-49 IGHV3-73 IGHV3-72	9.32e-09	5	35	3	10367906
Pubmed	Lineage-specific functions of TET1 in the postimplantation mouse embryo.	TET2 TET3 TET1	9.32e-09	5	35	3	28504700
Pubmed	An intrinsic propensity of murine peritoneal B1b cells to switch to IgA in presence of TGF-β and retinoic acid.	IGHV3-49 IGHV3-73 IGHV3-72	9.32e-09	5	35	3	24324757
Pubmed	Loss of adipose TET proteins enhances β-adrenergic responses and protects against obesity by epigenetic regulation of β3-AR expression.	TET2 TET3 TET1	9.32e-09	5	35	3	35737830
Pubmed	Dynamic expression of TET1, TET2, and TET3 dioxygenases in mouse and human placentas throughout gestation.	TET2 TET3 TET1	9.32e-09	5	35	3	29108636
Pubmed	CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases.	TET2 TET3 TET1	9.32e-09	5	35	3	25557551
Pubmed	TET-Mediated Sequestration of miR-26 Drives EZH2 Expression and Gastric Carcinogenesis.	TET2 TET3 TET1	9.32e-09	5	35	3	28923852
Pubmed	Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a.	TET2 TET3 TET1	9.32e-09	5	35	3	23820384
Pubmed	TET1 contributes to neurogenesis onset time during fetal brain development in mice.	TET2 TET3 TET1	1.86e-08	6	35	3	26902115
Pubmed	Maternal high-fat diet alters Tet-mediated epigenetic regulation during heart development.	TET2 TET3 TET1	1.86e-08	6	35	3	39262804
Pubmed	Downregulation of ten-eleven translocation-2 triggers epithelial differentiation during organogenesis.	TET2 TET3 TET1	5.21e-08	8	35	3	35569195
Pubmed	DNA methyltransferase 3b regulates articular cartilage homeostasis by altering metabolism.	TET2 TET3 TET1	5.21e-08	8	35	3	28614801
Pubmed	TET1 regulates fibroblast growth factor 8 transcription in gonadotropin releasing hormone neurons.	TET2 TET3 TET1	7.81e-08	9	35	3	31361780
Pubmed	Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies.	TET2 TET3 TET1	1.11e-07	10	35	3	31467060
Pubmed	A mutation in the tuft mouse disrupts TET1 activity and alters the expression of genes that are crucial for neural tube closure.	TET2 TET3 TET1	2.65e-07	13	35	3	26989192
Pubmed	Tet1 controls meiosis by regulating meiotic gene expression.	TET2 TET3 TET1	3.37e-07	14	35	3	23151479
Pubmed	Tet proteins influence the balance between neuroectodermal and mesodermal fate choice by inhibiting Wnt signaling.	TET2 TET3 TET1	4.21e-07	15	35	3	27930333
Pubmed	DNA dioxygenases Tet2/3 regulate gene promoter accessibility and chromatin topology in lineage-specific loci to control epithelial differentiation.	TET2 TET3 TET1	4.21e-07	15	35	3	36630508
Pubmed	TET2 catalyzes active DNA demethylation of the Sry promoter and enhances its expression.	TET2 TET3 TET1	4.21e-07	15	35	3	31530896
Pubmed	EHMT2 directs DNA methylation for efficient gene silencing in mouse embryos.	TET2 TET3 TET1	4.21e-07	15	35	3	26576615
Pubmed	Oct4 Methylation-Mediated Silencing As an Epigenetic Barrier Preventing Müller Glia Dedifferentiation in a Murine Model of Retinal Injury.	TET2 TET3 TET1	7.54e-07	18	35	3	27895551
Pubmed	TET2 and TET3 loss disrupts small intestine differentiation and homeostasis.	TET2 TET3	9.84e-07	2	35	2	37414790
Pubmed	TET enzymes control antibody production and shape the mutational landscape in germinal centre B cells.	TET2 TET3	9.84e-07	2	35	2	31120187
Pubmed	Distributive Processing by the Iron(II)/α-Ketoglutarate-Dependent Catalytic Domains of the TET Enzymes Is Consistent with Epigenetic Roles for Oxidized 5-Methylcytosine Bases.	TET2 TET1	9.84e-07	2	35	2	27362828
Pubmed	A primary role of TET proteins in establishment and maintenance of De Novo bivalency at CpG islands.	TET2 TET1	9.84e-07	2	35	2	27288448
Pubmed	Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination.	TET2 TET1	9.84e-07	2	35	2	30606231
Pubmed	Structural insight into substrate preference for TET-mediated oxidation.	TET2 TET1	9.84e-07	2	35	2	26524525
Pubmed	Ten-eleven translocation 2 modulates allergic inflammation by 5-hydroxymethylcytosine remodeling of immunologic pathways.	TET2 TET1	9.84e-07	2	35	2	34165552
Pubmed	Tet1 and Tet2 Protect DNA Methylation Canyons against Hypermethylation.	TET2 TET1	9.84e-07	2	35	2	26598602
Pubmed	Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors.	TET2 TET1	9.84e-07	2	35	2	30045709
Pubmed	Role of Chromatin Remodeling Genes and TETs in the Development of Human Midbrain Dopaminergic Neurons.	TET2 TET3	9.84e-07	2	35	2	32367481
Pubmed	Stage-specific roles for tet1 and tet2 in DNA demethylation in primordial germ cells.	TET2 TET1	9.84e-07	2	35	2	23415914
Pubmed	Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.	TET2 TET3	9.84e-07	2	35	2	32126143
Pubmed	Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice.	TET2 TET1	9.84e-07	2	35	2	26586431
Interaction	GAGE12B interactions	GMCL1 GMCL2	9.59e-06	4	26	2	int:GAGE12B
Interaction	GAGE12I interactions	GMCL1 GMCL2	9.59e-06	4	26	2	int:GAGE12I
Interaction	XAGE2 interactions	GMCL1 GMCL2	1.66e-04	15	26	2	int:XAGE2
Cytoband	14q32.33	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72	8.02e-31	228	34	17	14q32.33
Cytoband	Ensembl 112 genes in cytogenetic band chr14q32	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	2.88e-20	566	34	15	chr14q32
Cytoband	Ensembl 112 genes in cytogenetic band chr2p13	GMCL1 TET3	4.86e-03	140	34	2	chr2p13
GeneFamily	Immunoglobulin heavy locus at 14q32.33	IGHV3-49 IGHV3-48 IGHV3-30-3 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-43D IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72	9.54e-30	187	28	18	349
GeneFamily	Zinc fingers CXXC-type	TET3 TET1	1.51e-04	12	28	2	136
Coexpression	XU_CREBBP_TARGETS_DN	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	1.22e-22	56	31	11	MM642
Coexpression	YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6	IGHV3-48 PAM IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	8.20e-22	102	31	12	MM872
Coexpression	RASHI_RESPONSE_TO_IONIZING_RADIATION_6	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-64D	2.08e-20	132	31	12	MM996
Coexpression	MATTIOLI_MGUS_VS_PCL	IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	7.66e-09	127	31	6	M10973
Coexpression	SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12	IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-73 IGHV3-72	7.42e-08	318	31	7	M2429
Coexpression	SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_DN	IGHV3-48 IGHV3-7 IGHV3-74	8.30e-07	16	31	3	M41742
Coexpression	RICKMAN_HEAD_AND_NECK_CANCER_D	MUC5B IGHV3-73 IGHV3-72	1.44e-05	40	31	3	M19164
Coexpression	VANASSE_BCL2_TARGETS_UP	IGHV3-49 IGHV3-73 IGHV3-72	1.79e-05	43	31	3	MM799
Coexpression	POOLA_INVASIVE_BREAST_CANCER_UP	IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	2.22e-05	292	31	5	M5369
Coexpression	SMID_BREAST_CANCER_LUMINAL_B_DN	IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-7 TET3 HLA-G	5.62e-05	587	31	6	M17572
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000_k-means-cluster#5	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-72	2.52e-13	183	24	9	Arv_SC_fibroblast_1000_K5
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-72	2.52e-13	183	24	9	Arv_SC-HD_1000_K3
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	6.72e-12	163	24	8	Arv_SC-hpx_blastocyst_500_K2
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	1.19e-11	175	24	8	Arv_SC-H9hpx_500_K3
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-72	6.97e-11	126	24	7	Arv_SC-HD_500_K2
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-72	1.40e-10	139	24	7	Arv_SC_fibroblast_500_K3
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000_k-means-cluster#4	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	1.70e-10	244	24	8	Arv_SC-H9hpx_1000_K4
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	3.38e-10	266	24	8	Arv_SC-hpx_blastocyst_1000_K2
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	4.17e-08	492	24	8	Arv_SC-H9hpx_500
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	4.17e-08	492	24	8	Arv_SC-hpx_blastocyst_500
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 SLCO1A2 IGHV3-74 IGHV3-72	4.82e-08	986	24	10	Arv_SC_fibroblast_1000
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 SLCO1A2 IGHV3-74 IGHV3-72	4.82e-08	986	24	10	Arv_SC-HD_1000
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 MYO7B SLCO1A2 IGHV3-74	4.87e-08	987	24	10	Arv_SC-H9hpx_1000
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 MYO7B SLCO1A2 IGHV3-74	4.87e-08	987	24	10	Arv_SC-hpx_blastocyst_1000
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_2500_k-means-cluster#4	IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	3.21e-07	426	24	7	Arv_SC-hpx_blastocyst_2500_K4
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-72	8.11e-07	489	24	7	Arv_SC-HD_500
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-72	8.11e-07	489	24	7	Arv_SC_fibroblast_500
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_2500_k-means-cluster#5	IGHV3-33 IGHV3-30 IGHV3-23 MYO7B IGHV3-74 IGHV3-72	1.73e-06	341	24	6	Arv_SC_fibroblast_2500_K5
CoexpressionAtlas	ratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_2500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 HHAT	2.60e-06	848	24	8	ratio_ECTO_vs_SC_2500_K3
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_2500_k-means-cluster#2	IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	6.41e-06	428	24	6	Arv_SC-H9hpx_2500_K2
CoexpressionAtlas	geo_heart_top-relative-expression-ranked_2500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-7 MYO7B IGHV3-74 IGHV3-72	2.19e-05	1133	24	8	geo_heart_2500_K2
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_2500_k-means-cluster#4	IGHV3-33 IGHV3-30 MYO7B IGHV3-74 IGHV3-72	2.35e-05	315	24	5	Arv_SC-HD_2500_K4
CoexpressionAtlas	PP_HSC_top-relative-expression-ranked_2500_k-means-cluster#3	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-72	3.33e-05	339	24	5	PP_HSC_2500_K3
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_2500_k-means-cluster#2	IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 SLCO1A2 TET1	1.68e-04	1113	24	7	Arv_SC-HD_2500_K2
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_2500_k-means-cluster#2	IGHV3-48 IGHV3-21 IGHV3-9 IGHV3-7 SLCO1A2 TET1	1.19e-03	1108	24	6	Arv_SC_fibroblast_2500_K2
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells-IgA_plasma_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	7.32e-28	190	32	15	18762ce78ed0b206ade19e1c8ff76a2647489f68
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-73 IGHV3-72 IGHV3-64D	7.32e-28	190	32	15	79ee6d10dfbb775da149a1104da5823cf63bbb46
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV1-3 IGHV3-64D	2.61e-21	181	32	12	e47664a264a2c37390d1668ce04eef2e0172f4cb
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	5.75e-21	193	32	12	282b47dae6043eabb1e13d41d91c07b5ec21cd65
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72	6.13e-21	194	32	12	6ef4aeb8d8e35e4df58ff2a8256caa2113291de9
ToppCell	COVID_vent-Lymphocytic-Plasma_cell-IgM_Plasmablast\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-72	6.95e-21	196	32	12	026a06d8d2089806823e6f6453d3ede84ae93bc6
ToppCell	Biopsy_IPF-Immune-Plasma_cells\|Biopsy_IPF / Sample group, Lineage and Cell type	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-72	6.95e-21	196	32	12	a1b6a8000b86efcb07843998aa3a49bb1f54bcda
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	7.40e-21	197	32	12	2662138671262b30508c5759038bcdcfe6551696
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	5.03e-19	185	32	11	0fff2608f507e019ebb69c27e58fd5be3b049bef
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-64D	5.03e-19	185	32	11	79edc1eeb7b5b9123961ac3ecf398ee68d9dddb9
ToppCell	5'-Adult-LargeIntestine-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-74 IGHV1-3 IGHV3-72	7.20e-19	191	32	11	d1d30279ed4612b4f62c225d9eabf0b8a7a09d11
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell-IgM_Plasmablast\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72	8.09e-19	193	32	11	7b4b0271e4fbece703876acb053ae236afb7cdba
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-74 IGHV3-72	8.09e-19	193	32	11	34f6c13884fdf7f8a87f942fcb36a58cfac3f65d
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-72	9.08e-19	195	32	11	df009b18898c10686f75cf72b4ec0eff18f5bb50
ToppCell	367C-Lymphocytic-Plasma_cell-\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	2.27e-17	167	32	10	f2185eb72f0137136f6d71af2a70168fded6c940
ToppCell	367C-Lymphocytic-Plasma_cell\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	2.27e-17	167	32	10	5e768cf24699893e05d1bcb1c92dba2336943a64
ToppCell	BAL-Mild-Lymphocyte-B\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV1-3 IGHV3-64D	2.56e-17	169	32	10	307571e57c3bfdf15f0fe1a8b36585e8e4f8a207
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-73 IGHV3-64D	3.26e-17	173	32	10	0ca2169a275404118038c0489a48062879488765
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	6.44e-17	185	32	10	08bc817908076734d66f2805cb954141f2cc5a18
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	6.44e-17	185	32	10	1704a12153a9b107bf03ecccd1a036cf61334d7a
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	1.04e-16	194	32	10	a4a70369541876e1192df8828b63e3d1746ae3d9
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72	1.10e-16	195	32	10	f3f7f1a77a1edd2b50a8211c76fe289738eb04cf
ToppCell	Biopsy_Other_PF-Immune-Plasma_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV1-3 IGHV3-72	1.10e-16	195	32	10	d0305c6a68c9e361507b04db94f86873085d49b3
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	1.16e-16	196	32	10	fec21383435779bf4c632decd3d29c6ca7baebfb
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	1.22e-16	197	32	10	1e63879633f20646e44873ae6b662f6faf4806fd
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell-B_naive\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-73	1.28e-16	198	32	10	79c690d21d3420d0bb1a3b3b4ea2c9aa3810a219
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	3.87e-15	173	32	9	7e6bfe85f60834f317941b70d6e0dc3bd527d293
ToppCell	COPD-Lymphoid-B_Plasma\|World / Disease state, Lineage and Cell class	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-64D	4.30e-15	175	32	9	d73ee324479172501481b54967a0f3bd870fcf3a
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	4.77e-15	177	32	9	c2b0fb5921eea24d248d6e6ccb57c29b0832602c
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	4.77e-15	177	32	9	111fb0707ff37ca631d85bb5a09e067ffe568eb8
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-74	5.02e-15	178	32	9	107dae8b00c4257697a63700e72bb434cdb8406f
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74 IGHV3-72	5.28e-15	179	32	9	837ed81f18257f444eaeadc4fac89deedd4e3061
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74 IGHV3-72	5.28e-15	179	32	9	b6ee4f41d8fb5f047b7bdd8489dda0a89fc6d43f
ToppCell	Mild_COVID-19-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-73	6.47e-15	183	32	9	dea119e2988e954475f557f0bbe12556a83e81a4
ToppCell	cellseq-Immune-Lymphocytic_B-Lymphocytic_B-Plasma\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-74	6.47e-15	183	32	9	5ab4aa0304b832f98fff89b6c24ad5b7dd014c11
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	6.79e-15	184	32	9	15f2c10101ccc8ed059520fc082ee42593dff269
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	6.79e-15	184	32	9	a90a58d9e319afa1cd572e4c2f516fadc42f56e5
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	1.15e-14	195	32	9	13f4ee21568fd747608412d33559d10561dbb3c8
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	1.21e-14	196	32	9	c38e7f533c619afe008de0e99042f7180c2da918
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	1.27e-14	197	32	9	9fe1b757f76c2d43d39aa9ac500eaba98723985c
ToppCell	Control-Control-Lymphocyte-B-Plasmablast\|Control / Disease, condition lineage and cell class	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	1.39e-14	199	32	9	c11aa8bca3723a886e7082ae48bb922dd8396be4
ToppCell	healthy_donor-Lymphocytic-Plasma_cell-IgG_Plasmablast\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-43 IGHV3-21 IGHV3-20 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72	1.38e-13	152	32	8	a2ba2d95ac9010e1a62db34dcad10d004f8a90cc
ToppCell	Control-Lymphoid_P\|Control / Disease group, lineage and cell class	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	4.53e-13	176	32	8	d895a6b295cd649273ff80ad7785a3e0ae4c728a
ToppCell	Control-Lymphoid_P-Plasmablast\|Control / Disease group, lineage and cell class	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74	4.53e-13	176	32	8	4b4416f342b732d2cc60133838728880326257d8
ToppCell	VE-plasma\|VE / Condition, Cell_class and T cell subcluster	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	4.75e-13	177	32	8	0c1cc0834de55717cb4f69d020339060ce2c9a03
ToppCell	-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	4.75e-13	177	32	8	ae2d2e138946535596fa30a55207f261cafda461
ToppCell	VE-plasma-\|VE / Condition, Cell_class and T cell subcluster	IGHV3-49 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	4.75e-13	177	32	8	3a3c94cf30012e2aa266bc4d7fe772e45fa90f6d
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	4.75e-13	177	32	8	4c434a7b7cc54cf4dac996bbc3f5124d9ef9a9cd
ToppCell	(2)_Plasma_cells\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	4.75e-13	177	32	8	ed3c936bb69f9bc7291b4f6cde1d204078117c48
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	4.75e-13	177	32	8	d746122bf8d208c3aa4d156e8c12d0a0e555c6e5
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	4.75e-13	177	32	8	fc40918825b7e1eb6861df59dfca944778a64b98
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-72	5.20e-13	179	32	8	494febe77c6d4e6a2c6f0928bbf4c84b0301f188
ToppCell	BAL-Severe-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-49 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-72	5.44e-13	180	32	8	6a777a308fa3160d31eda468db930e71862020b2
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV1-3 IGHV3-73 IGHV3-72	5.44e-13	180	32	8	e3877f6ef5f54ff689058b4c996ab1851822f871
ToppCell	10x5'-Liver-Lymphocytic_B_plasma-Plasma_cells\|Liver / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72 IGHV3-64D	6.49e-13	184	32	8	6f70d8f8ab8362d51f8a58735d42223e06566397
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7 IGHV3-74 IGHV3-72	7.72e-13	188	32	8	6844cebca177fdf38b21a40d606230a033717a3a
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)-lymphocytic-B_lymphocytic-plasma_cell\|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3 IGHV3-72	8.06e-13	189	32	8	5a42be62552d912d0abf68f00d75ac80bbd69f2c
ToppCell	COVID-19-Lymphoid-Plasma,_B_cells\|COVID-19 / Condition, Lineage and Cell class	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-7 IGHV3-74	9.54e-13	193	32	8	bffd97a73365e1dd23ff3b0320b4860f04ec091a
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV1-3	9.54e-13	193	32	8	5c5543e7c83ecea44d23521246592c0301044173
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-74 IGHV1-3	1.04e-12	195	32	8	0b0615553b9a1b60d666d074ce4260919e2d5642
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	1.13e-12	197	32	8	88b29d205237f07a9a26cc15a1cf4ed4816a4c4b
ToppCell	Biopsy_Control_(H.)-Immune-Plasma_cells\|Biopsy_Control_(H.) / Sample group, Lineage and Cell type	IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	1.13e-12	197	32	8	275f38ed7e477000e864cecf9b7d49ae134c3b6a
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13	1.13e-12	197	32	8	76465bb2408c7c75f694e8f7cf1a606b796afc3a
ToppCell	3'_v3-blood-Lymphocytic_B_plasma-Plasma_cells\|blood / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-23 IGHV3-20 IGHV3-7 IGHV3-74	2.45e-11	165	32	7	1c0c24fe252b761cf879b83562e23c02f0b6489f
ToppCell	tumor_Lung-B_lymphocytes-Plasma_cells\|tumor_Lung / Location, Cell class and cell subclass	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-7 IGHV3-73 IGHV3-72	2.90e-11	169	32	7	b36b7632ce55fc7b6b8b66020563d360b3de6fd7
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell-B_activate-7\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-64D	3.02e-11	170	32	7	ee2ee67d90ae4596de8ccd620e37c82cf51651d4
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-64D	3.02e-11	170	32	7	d7ca0c6ce5d2b7de99346f87e07aa7fe728fa08a
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-64D	3.02e-11	170	32	7	52787f6d529c285d9f0c04cc022710ead5b89b3f
ToppCell	metastatic_Brain-B_lymphocytes-MALT_B_cells\|metastatic_Brain / Location, Cell class and cell subclass	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	3.85e-11	176	32	7	50e207403d48ce1b55a78897adb5519a2430a626
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	4.51e-11	180	32	7	cea079bc02e08c46600eed05ab9924ec90e1e3d3
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-plasma_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	4.69e-11	181	32	7	f7b08f662eb77ee7a777c6525ddc3195046aaf65
ToppCell	3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-72	4.88e-11	182	32	7	1bf2e4fd6222b41a7d08df6dcc500c9401db8c18
ToppCell	Mild-Lymphoid-B\|Mild / Condition, Lineage, Cell class and cell subclass	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-72 IGHV3-64D	5.07e-11	183	32	7	9b64d2d143525e6f48a191facfd101462ff36324
ToppCell	Mild-Lymphoid-B-\|Mild / Condition, Lineage, Cell class and cell subclass	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-72 IGHV3-64D	5.07e-11	183	32	7	b5740f05a4dcdbbf24f7bf7a3f57ac01a5e75f60
ToppCell	3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-72 IGHV3-64D	5.07e-11	183	32	7	cf5c98f451a568308c52da5c926543dd4836c6b2
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-64D	5.47e-11	185	32	7	609080adb2cfb105bb7b8efb617553833299f371
ToppCell	10x5'-Liver-Lymphocytic_B_plasma\|Liver / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-23 IGHV3-7 IGHV3-74 IGHV3-73 IGHV3-72 IGHV3-64D	5.68e-11	186	32	7	a2c7430781f432c9c90ac4d620f4518ff767a223
ToppCell	Mild_COVID-19-B_cell-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-73	5.68e-11	186	32	7	855a5a00ba2aa1b5c63b8db56d026ddecc546050
ToppCell	5'-GW_trimst-2-LymphNode-Hematopoietic-B_cells-Immature_B\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV1-3	5.68e-11	186	32	7	459a7e97bbac2b2cd253aa4ab38d0e4ae6191e8b
ToppCell	3'_v3-bone_marrow-Lymphocytic_B_plasma\|bone_marrow / Manually curated celltypes from each tissue	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74 IGHV3-72	6.36e-11	189	32	7	dceb011216deb4ffd830144a53c635c05dff5ec5
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-74	7.10e-11	192	32	7	3dddfc93c3c954c4416c7c1f1f161e4d1dcc1233
ToppCell	Control-B_cell-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.37e-11	193	32	7	d43099c0b8ca68048d6497c4db89d6d5155375f9
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.37e-11	193	32	7	bcda1fb3db7d4c276e3370250a2b79fedd807fc5
ToppCell	BAL-Control-Lymphocyte-B-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.37e-11	193	32	7	ba826e6e035e48e1b497af1081c43339b0019e76
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.37e-11	193	32	7	befab58da635723db4f9270d087afa981fc45bf1
ToppCell	BAL-Control-Lymphocyte-B\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.64e-11	194	32	7	1537e2285d0a8d0a4175dd0b8b1d1ccd887229fc
ToppCell	Control-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	7.64e-11	194	32	7	8388fe4df3461d85b21bd6847a4d32c030aaece4
ToppCell	5'-Adult-LargeIntestine\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-48 IGHV3-33 MUC5B IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-74	7.92e-11	195	32	7	600174e35574fe7c44dd923adcf43686e7b01e39
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-74	8.21e-11	196	32	7	b3d5540fe8ab9a9cbb9ab5350f5cb0e1aae93584
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	8.21e-11	196	32	7	e9fe5090452ffdde4bb81b62d57037d823281d00
ToppCell	Lung_Parenchyma-Severe-Lymphocyte-B-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3	8.51e-11	197	32	7	365654a344bfdd2533cfcbed05063427b40f47b9
ToppCell	Parenchyma_COVID-19-Immune-TX-Plasma_cells\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3	8.51e-11	197	32	7	3259d7ce3e6dde1beda8b534bdf7ff5c7fc1a46c
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell-IgA_Plasmablast\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-72	8.51e-11	197	32	7	fdbf4eb9fa5aefb4ffb307494fe4774bf5e0aaeb
ToppCell	Lung_Parenchyma-Severe-Lymphocyte-B-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3	8.51e-11	197	32	7	9936dc179aa0cf8aadf77946b26c09ad33848dc2
ToppCell	Lung_Parenchyma-Severe-Lymphocyte-B-Plasmablast-Plasmablast-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3	8.51e-11	197	32	7	5474774c2ff7a13ec1a020e2fef4efa72e34727b
ToppCell	Lung_Parenchyma-Severe-Lymphocyte-B\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV1-3	8.51e-11	197	32	7	9e0850b6bb952757c74ba816e30006199e562bfa
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_cell-B_mature\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74 IGHV3-72	8.51e-11	197	32	7	da175e66d0a743a1b91d46f224b5ff1d37aa5410
ToppCell	COVID_vent-Lymphocytic-Plasma_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-9 IGHV3-7	8.81e-11	198	32	7	e84c5f712e1dea548d0e2aba6625598f9671d3a0
ToppCell	metastatic_Lymph_Node-B_lymphocytes-Plasma_cells\|metastatic_Lymph_Node / Location, Cell class and cell subclass	IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-73	7.53e-10	142	32	6	5ba3a33c2ee20be8baaed97536ca6e9d1de6752f
ToppCell	10x5'-blood-Lymphocytic_B_plasma\|blood / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-33 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	1.05e-09	150	32	6	6bab0a8bf78ed7de9e1b67ede7496488f80f4863
Drug	5-Methylcytosine	TET2 TET3 TET1	3.46e-10	3	17	3	ctd:D044503
Drug	5-hydroxymethylcytosine	TET2 TET3 TET1	3.45e-09	5	17	3	ctd:C011865
Drug	2,3,5,6-tetrachlorohydroquinone	TET2 TET1	1.47e-05	8	17	2	ctd:C044578
Drug	4-cpp	GMCL1 GMCL2	2.87e-05	11	17	2	CID000018703
Drug	Chloranil	TET2 TET1	7.97e-05	18	17	2	ctd:D002703
Drug	diethyl phosphate	PAM GMCL1 GMCL2	8.97e-05	119	17	3	CID000000654
Drug	TETs	TET2 TET1	1.20e-04	22	17	2	CID000064148
Disease	fibroblast growth factor 8 isoform A measurement	IGHV3-7 IGHV3-64D	7.47e-07	2	26	2	EFO_0020385
Disease	dynein light chain 1, cytoplasmic measurement	IGHV3-7 IGHV3-64D	2.24e-06	3	26	2	EFO_0020339
Disease	tumor necrosis factor ligand superfamily member 11 measurement	IGHV3-21 IGHV3-7	5.79e-05	13	26	2	EFO_0010617
Disease	colorectal cancer, endometrial neoplasm	TET2 GMCL1	6.29e-04	42	26	2	EFO_0004230, MONDO_0005575
Disease	cystic fibrosis (is_marker_for)	MUC5B HLA-G	1.37e-03	62	26	2	DOID:1485 (is_marker_for)
Disease	allergic sensitization measurement	IGHV3-73 IGHV3-72	1.37e-03	62	26	2	EFO_0005298
Disease	esophagus squamous cell carcinoma (is_marker_for)	TET2 TET3	1.94e-03	74	26	2	DOID:3748 (is_marker_for)
Disease	reaction time measurement	TET2 TMEM229A HHAT TET1	2.48e-03	658	26	4	EFO_0008393
Disease	Autism Spectrum Disorders	TET3 TET1	2.55e-03	85	26	2	C1510586
Disease	gestational age	TMEM229A TET3	6.56e-03	138	26	2	EFO_0005112
Disease	serum metabolite measurement	IGHV3-49 IGHV3-48 SLCO1A2 HHAT	8.91e-03	945	26	4	EFO_0005653
Disease	susceptibility to childhood ear infection measurement	SLCO1A2 HLA-G	9.90e-03	171	26	2	EFO_0007904

Protein segments in the cluster

Peptide	Gene	Start	Entry
LFGCNMPSSTGSYWF	PAM	106	P19021
QFFCGFSSSTMIDYW	ATP10B	1131	O94823
LCQSGYFSSMFSGSW	GMCL1	126	Q96IK5
SMWGGSHYSTFDGTS	MUC5B	5076	Q9HC84
ETWAGSHSMRYFSAA	HLA-G	21	P17693
CAASGFTFSDHYMDW	IGHV3-72	41	A0A0B4J1Y9
CAASGFTFDDYAMHW	IGHV3-43D	41	P0DP04
CAASGFTFSSYGMHW	IGHV3-30-5	41	P0DP03
CAASGFTFSSYWMSW	IGHV3-7	41	P01780
CAASGFTFSSYAMHW	IGHV3-30-3	41	P0DP02
CAASGFTFDDYAMHW	IGHV3-9	41	P01782
CAASGFTFSSYDMHW	IGHV3-13	41	P01766
CAASGFTFSSYEMNW	IGHV3-48	41	P01763
CAASGFTFDDYGMSW	IGHV3-20	41	A0A0C4DH32
CSASGFTFSSYAMHW	IGHV3-64D	41	A0A0J9YX35
CAASGFTFSSYWMHW	IGHV3-74	41	A0A0B4J1X5
CTASGFTFGDYAMSW	IGHV3-49	41	A0A0A0MS15
CKASGYTFTSYAMHW	IGHV1-3	41	A0A0C4DH29
CAASGFTFSSYSMNW	IGHV3-21	41	A0A0B4J1V1
CAASGFTFDDYTMHW	IGHV3-43	41	A0A0B4J1X8
FSTAMTFAFVSYWHG	HHAT	366	Q5VTY9
CAASGFTFSSYAMSW	IGHV3-23	41	P01764
CAASGFTFSSYGMHW	IGHV3-30	41	P01768
WNSSSTEFCAVYGFM	EIF2A	281	Q9BY44
CAASGFTFSSYGMHW	IGHV3-33	41	P01772
CAASGFTFSGSAMHW	IGHV3-73	41	A0A0B4J1V6
TTSGHTSLWSFFMYG	TMEM229A	271	B2RXF0
TSLWSFFMYGSCSFV	TMEM229A	276	B2RXF0
LCQSGYFSSMFSGSW	GMCL2	126	Q8NEA9
YFGALMDSTCLHWGT	SLCO1A2	566	P46721
CGASFSFGCSWSMYF	TET1	1571	Q8NFU7
SFGCSWSMYFNGCKF	TET1	1576	Q8NFU7
CGASFSFGCSWSMYF	TET3	976	O43151
MSSKDFFACGHSGHW	ZCCHC13	1	Q8WW36
SFHYFSMGDCIGWLE	ULBP2	181	Q9BZM5
CGASFSFGCSWSMYY	TET2	1281	Q6N021
SWSSGSTYFHMALGS	MYO7B	2056	Q6PIF6